From: Multi-omics gut microbiome signatures in obese women: role of diet and uncontrolled eating behavior
 | C1 | C2 | C3 | C4 | p | ||||
 | N | Median (p25-p75) | N | Median (p25-p75) | N | Median (p25-p75) | N | Median (p25-p75) | |
Anthropometric, biochemical, and hormonal parameters | |||||||||
 Age (years) | 31 | 34 (26–42) | 33 | 32 (26–44) | 22 | 40 (30–45) | 14 | 32 (27–41) | 0.959 |
 Body weight (kg) | 31 | 70.5 (58.0–80.0) | 33 | 77.8 (65.5–89.5) | 22 | 76.5 (57.5–85.5) | 14 | 76.5 (59.6–89.4) | 0.190 |
 Body mass index, BMI (kg/m2) | 31 | 25.6 (21.2–30.5) | 33 | 29.7 (24.4–33.0) | 22 | 28.2 (21.8–31.8) | 14 | 28.6 (22.6–32.9) | 0.160 |
 Systolic blood pressure (mmHg) | 31 | 115.0 (110.0–125.0) | 32 | 120.0 (111.3–130.0) | 22 | 112.5 (108.8–130.0) | 14 | 120.0 (110.0–130.0) | 0.287 |
 Diastolic blood pressure (mmHg) | 31 | 70.0 (70.0–80.0) | 32 | 77.5 (70.0–80.0) | 22 | 70.0 (65.0–75.0) | 14 | 80.0 (70.0–81.3) | 0.150 |
 Waist circumference (cm) | 31 | 88.0 (77.0–106.0) | 33 | 96.0 (89.0–102.5) | 22 | 95.5 (76.8–104.0) | 14 | 94.0 (83.0–101.3) | 0.258 |
 Hip circumference (cm) | 28 | 105.0 (94.5–112.0) | 27 | 109.0 (101.0–117.0) | 20 | 103.0 (95.0–115.0) | 13 | 106.0 (97.0–120.0) | 0.274 |
 Waist-to-hip ratio | 28 | 0.83 (0.79–0.92) | 27 | 0.87 (0.83–0.91) | 20 | 0.84 (0.81–0.90) | 13 | 0.88 (0.79–0.92) | 0.701 |
 Total cholesterol (mg/dl) | 31 | 175.0 (164.0–202.0) | 33 | 170.0 (155.5–211.5) | 22 | 193.0 (168.3–208.8) | 14 | 185.5 (161.8–194.0) | 0.718 |
 HDL-cholesterol (mg/dl) | 31 | 58.0 (47.0–64.0) | 33 | 53.0 (47.5–59.0) | 22 | 56.5 (45.5–59.8) | 14 | 56.5 (46.0–68.5) | 0.148 |
 Triglycerides (mg/dl) | 31 | 69.0 (51.0–106.0) | 33 | 85.0 (60.5–106.0) | 22 | 70.0 (56.5–98.8) | 14 | 63.0 (47.5–91.5) | 0.077(a) |
 LDL-cholesterol (mg/dl) | 30 | 105.5 (96.8–125.0) | 33 | 110.0 (91.0–131.5) | 20 | 115.0 (100.0–143.8) | 14 | 107.0 (92.8–126.0) | 0.940 |
 Glycemia (mg/dl) | 31 | 85.0 (80.0–89.0) | 33 | 86.0 (81.0–91.0) | 22 | 88.0 (84.8–90.8) | 14 | 81.0 (78.5–90.3) | 0.600 |
 Glycemia-AUC (mg/dl) | 31 | 12,630 (10,725–15,000) | 31 | 13,095 (10,515–14,715) | 22 | 13,148 (11,351–14,554) | 14 | 12,998 (10,890–14,738) | 0.911 |
 Insulin (μU/ml) | 31 | 5.9 (3.2–13.0) | 33 | 9.0 (4.8–12.0) | 22 | 6.0 (4.1–13.0) | 14 | 6.0 (3.9–10.6) | 0.383 |
 Insulin-AUC (μU/ml) | 31 | 4709 (2670–7095) | 31 | 7155 (4430–9725) | 21 | 4016 (3460–7379) | 14 | 5264 (3735–7728) | 0.054(b) |
 Glycated hemoglobin (%) | 31 | 5.2 (4.9–5.4) | 33 | 5.3 (5.0–5.4) | 22 | 5.1 (4.9–5.4) | 14 | 5.2 (4.7–5.4) | 0.371 |
 Creatinine (mg/dl) | 10 | 0.72 (0.63–0.85) | 20 | 0.75 (0.60–0.82) | 9 | 0.77 (0.63–0.90) | 6 | 0.71 (0.67–0.77) | 0.917 |
 Alanine transaminase, ALT (mg/dl) | 10 | 19.0 (14.3–24.0) | 21 | 18.0 (12.0–24.5) | 9 | 17.0 (13.5–28.5) | 6 | 14.0 (9.8–17.0) | 0.180 |
 Aspartate transaminase, AST (mg/dl) | 10 | 17.0 (14.8–22.3) | 21 | 16.0 (13.0–20.0) | 9 | 20.0 (15.0–23.5) | 6 | 15.0 (12.3–17.0) | 0.427 |
 Uric acid (mg/dl) | 10 | 4.4 (3.7–4.8) | 21 | 4.4 (4.0–5.1) | 7 | 3.9 (3.6–4.3) | 5 | 3.5 (3.4–3.9) | 0.023(a) |
 C-reactive protein | 9 | 0.4 (0.1–0.5) | 21 | 0.3 (0.1–0.5) | 8 | 0.2 (0.1–0.4) | 5 | 0.8 (0.5–0.23) | 0.253 |
 Thyroid stimulating hormone, TSH (mUI/ml) | 10 | 1.43 (0.37–2.11) | 20 | 1.85 (1.51–2.38) | 10 | 1.48 (1.22–1.78) | 7 | 0.84 (0.80–1.59) | 0.059(a) |
 Adrenocorticotropic hormone, ACTH (pg/ml) | 10 | 21.0 (11.0–29.3) | 21 | 17.0 (12.5–23.0) | 8 | 16.5 (13.0–23.8) | 6 | 14.5 (11.5–22.0) | 0.771 |
 HOMA-IR | 31 | 1.24 (0.66–2.60) | 33 | 1.91 (0.97–2.71) | 22 | 1.37 (0.83–2.96) | 14 | 1.17 (0.77–2.37) | 0.466 |
 MATSUDA Index | 29 | 6.90 (3.55–10.10) | 30 | 5.15 (2.90–7.93) | 20 | 7.05 (3.83–10.35) | 13 | 5.20 (3.90–9.45) | 0.442 |
 | N | Mean ± sd | N | Mean ± sd | N | Mean ± sd | N | Mean ± sd |  |
Psychometric parameters | |||||||||
 BITE severity score | 30 | 4.73 ± 4.56 | 30 | 4.87 ± 5.24 | 19 | 4.31 ± 4.16 | 9 | 2.66 ± 1.73 | 0.124 |
 BITE symptom score | 30 | 6.23 ± 5.63 | 30 | 5.40 ± 5.66 | 19 | 7.26 ± 6.64 | 9 | 9.77 ± 4.87 | 0.108 |
 TFEQ UE | 29 | 17.10 ± 5.55 | 30 | 16.40 ± 5.87 | 19 | 16.95 ± 4.73 | 12 | 17.82 ± 5.21 | 0.254 |
 TFEQ CR | 29 | 15.31 ± 5.30 | 30 | 14.36 ± 3.79 | 19 | 13.16 ± 2.77 | 12 | 13.92 ± 4.66 | 0.448 |
 TFEQ EE | 29 | 7.06 ± 1.49 | 30 | 7.80 ± 2.98 | 19 | 7.42 ± 3.48 | 12 | 8.50 ± 2.35 | 0.198 |
 YFAS symptoms | 31 | 1.93 ± 1.41 | 33 | 2.36 ± 1.56 | 22 | 2.41 ± 1.47 | 14 | 2.64 ± 1.95 | 0.968 |
 YFAS diagnosed addiction | 2 | 6.4% | 6 | 18.2% | 4 | 18.2% | 2 | 14.3% | 0.242 |
 PSS | 31 | 14.77 ± 6.27 | 32 | 16.06 ± 6.74 | 21 | 14.81 ± 6.88 | 12 | 17.33 ± 4.94 | 0.380 |